ClinicalTrials.gov
ClinicalTrials.gov Menu

Rapamycin and Regulatory T Cells in Kidney Transplantation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01014234
Recruitment Status : Completed
First Posted : November 16, 2009
Last Update Posted : March 25, 2015
Sponsor:
Information provided by (Responsible Party):
Carmelo Libetta, IRCCS Policlinico S. Matteo

Brief Summary:

The immune system response is mediated by the interaction between the antigen presenting cell (APC), CD4+ T helper cells (Th) and CD4+ CD25+ regulatory T cells, a subgroup of CD4+ T cell which express IL-2 receptor (CD25) and the transcriptional factor foxp3. Regulatory T cell may contribute to the maintenance of tolerance by suppressing the immune response to normal or tumor associated antigens.

Regulatory T cell emerge from the thymus during ontogenesis and they represent about 10 % of the peripheral Cd4+ t cells.

Rapamycin is one the most use treatment to prevent renal allograft failure. Differently from calcineurin inhibitors (cyclosporine and tacrolimus), that inhibit T-cell activation through the inhibition of calcineurin activation, rapamycin inhibits cellular proliferation by impairing the progression of the cellular cycle, in particular by interaction with mTOR. Recently Battaglia et al. have demonstrated a Treg amplification in murine CD4+ lymphocytes treated with rapamycin in vitro.

Aim of the study is to evaluate the effect of different immunosuppressive regimens on regulatory T cell and to verify the hypothesis that rapamycin may induce tolerance in kidney transplanted patients, more than cyclosporine treatment.


Condition or disease Intervention/treatment Phase
Kidney Transplantation Drug: Cyclosporins Drug: Rapamycin Phase 2

Detailed Description:

It is two years randomised controlled trial in parallel groups.

It has been resolved to compare different immunosuppressive regimens:

  1. cyclosporine+ mycophenolate+prednisone
  2. rapamycin + mycophenolate + prednisone, this treatment should be introduced after one month from renal transplantation.

Patient should visited at month 1-6-12-24 from the transplant. During the control we will reported the following data: physical examination, blood test (blood count, creatinin, BUN, immunosuppressive blood concentration, histological response of surveillance renal biopsy), blood pressure, attendant change of current therapy, pathological variation, or any hospitalisation both ordinary or in DH regimen.

Moreover in all control visit it will be collected a blood sample for evaluation of regulatory t cells.


Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 56 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Rapamycin and Regulatory T Cells in Renal Transplant Patients: a Two-year Randomized Prospective Study
Study Start Date : July 2008
Actual Primary Completion Date : June 2013
Actual Study Completion Date : June 2013

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: Rapamycin
Maintenance treatment with rapamycin + mycophenolate + prednisone. This treatment will be introduced one month after renal transplantation.
Drug: Rapamycin
These patients will undergo maintenance immunosuppressive treatment with rapamycin + mycophenolate + prednisone according to established clinical practice. The dosage of drugs will be based on evaluations of serum trough levels and it will be adjusted when necessary.
Other Names:
  • Sirolimus
  • Rapamune
Active Comparator: cyclosporine
Maintenance treatment with cyclosporine + mycophenolate + prednisone. This treatment will be introduced one month after renal transplantation.
Drug: Cyclosporins
These patients will undergo maintenance immunosuppressive treatment with cyclosporine + mycophenolate + prednisone according to established clinical practice. The dosage of drugs will be based on evaluations of serum trough levels and it will be adjusted when necessary.
Other Name: Neoral



Primary Outcome Measures :
  1. The absolute number of T-reg after renal transplant in patients in treatment with rapamycin compared to patients treated with cyclosporine [ Time Frame: Every 6 months after the transplantation ]

Secondary Outcome Measures :
  1. Adverse events developed during the duration of the clinical study, that damage the patient, that is not part of the natural history of the disease. [ Time Frame: Every two months during the follow-up ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male and female aged from 18 to 75 years
  • Transplanted patients from cadaveric donors
  • Patients who has given written informed consensus

Exclusion Criteria:

  • Legally unable patients
  • Patients who have been participated to others studies in the last 3 months
  • Addicted to alcohol or smoking

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01014234


Locations
Italy
Policlinico Fondazione IRCCS "San Matteo"
Pavia, Italy, 27100
Sponsors and Collaborators
IRCCS Policlinico S. Matteo
Investigators
Principal Investigator: Antonio Dal Canton, MD Policlinico Fondazione IRCCS "San Matteo", Pavia

Publications:
Responsible Party: Carmelo Libetta, MD, IRCCS Policlinico S. Matteo
ClinicalTrials.gov Identifier: NCT01014234     History of Changes
Other Study ID Numbers: 20070034809
First Posted: November 16, 2009    Key Record Dates
Last Update Posted: March 25, 2015
Last Verified: March 2015

Keywords provided by Carmelo Libetta, IRCCS Policlinico S. Matteo:
Immunosuppressive Agents
Immune system regulation
Regulatory T cells
Rapamycin
Tolerance

Additional relevant MeSH terms:
Prednisone
Mycophenolic Acid
Sirolimus
Everolimus
Cyclosporins
Cyclosporine
Immunosuppressive Agents
Anti-Inflammatory Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Immunologic Factors
Antifungal Agents
Anti-Infective Agents
Dermatologic Agents
Antirheumatic Agents
Calcineurin Inhibitors
Antibiotics, Antineoplastic
Antibiotics, Antitubercular
Antitubercular Agents
Anti-Bacterial Agents